Nuformix PLC Annual Financial Report (5388H)
01 Agosto 2019 - 3:30AM
UK Regulatory
TIDMNFX
RNS Number : 5388H
Nuformix PLC
01 August 2019
Nuformix Plc
("Nuformix" or the "Company")
2019 Annual Financial Report and Notice of Annual General
Meeting
Cambridge, UK, 1 August 2019: Nuformix (LSE: NFX), the
pharmaceutical development company using cocrystal technology to
unlock the therapeutic potential of approved small molecule drugs,
is pleased to announce that the following documents have been
posted to its shareholders:
-- Annual Financial Report 2019
-- 2019 Notice of Annual General Meeting
A full pdf version of the Annual Financial Report 2019 together
with the Notice of Annual General Meeting will be available for
download from the Investor Information section on the Company's
website www.nuformix.com.
Copies of the Annual Financial Report 2019 and the Notice of
2019 Annual General Meeting will be submitted to the National
Storage Mechanism shortly and be available for inspection at
http://www.morningstar.co.uk/uk/NSM. The Nuformix Annual Financial
Report will be filed with the Registrar of Companies in due course
and copies can be obtained from the Company Secretary, SGH Company
Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.
The Annual General Meeting will be held on Tuesday 10 September
2019 at 1.00 pm at the offices of Shakespeare Martineau, 6(th)
floor, 60 Gracechurch Street, London, EC3V 0HR.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 627222
Optimum Strategic Communications
Mary Clark, Supriya Mathur +44 (0) 203 950
Email: nuformix@optimumcomms.com 9144
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSVFLBBKVFFBBB
(END) Dow Jones Newswires
August 01, 2019 04:30 ET (08:30 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024